Skocz do pozycji: 1.

Tytuł:

Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia-Single-Centre Experience.

Autorzy:

Stavi V; Soroka Medical Center, Beer Sheva 84101, Israel.
Khaire N; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Lipton JH; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Kumar R; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.

Pokaż więcej

Źródło:

Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Feb 26; Vol. 31 (3), pp. 1246-1252. Date of Electronic Publication: 2024 Feb 26.

Typ publikacji:

Case Reports

MeSH Terms:

Anemia, Aplastic*/therapy
Hematopoietic Stem Cell Transplantation*/methods
Graft vs Host Disease*
Humans ; Retrospective Studies ; Transplantation Conditioning/methods

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 2.

Tytuł:

Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes.

Autorzy:

Chen J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Pang A; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Zhao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Liu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Ma R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Wei J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Chen X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
He Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Yang D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Zhang R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Zhai W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Ma Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Jiang E; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Han M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Zhou J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
Feng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 293-299.

Typ publikacji:

Journal Article

MeSH Terms:

Graft Rejection/*physiopathology
Hematopoietic Stem Cell Transplantation/*adverse effects
Transplantation Conditioning/*adverse effects
Transplantation, Homologous/*adverse effects
Adolescent ; Adult ; Case-Control Studies ; Female ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Male ; Middle Aged ; Risk Factors ; Transplantation Conditioning/methods ; Transplantation, Homologous/methods ; Treatment Outcome ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 3.

Tytuł:

Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study.

Autorzy:

Gao L; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Yang L; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Tongren Hospital Shanghai Jiao Tong University School of Medicine, 111 Xianxia Road, Shanghai, China.
Zhou S; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Zhu W; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Han Y; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Chen S; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Xue S; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Wang Y; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China.
Qiu H; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. .; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China. .
Wu D; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. .; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China. .
Wu X; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. .; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China. .; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. .

Pokaż więcej

Źródło:

Stem cell research & therapy [Stem Cell Res Ther] 2024 Jan 29; Vol. 15 (1), pp. 24. Date of Electronic Publication: 2024 Jan 29.

Typ publikacji:

Journal Article

MeSH Terms:

Leukemia, Myeloid, Acute*/therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Myelodysplastic Syndromes*/therapy
Aged ; Humans ; Middle Aged ; Retrospective Studies ; Transplantation Conditioning ; China

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 4.

Tytuł:

Second haploidentical bone marrow transplantation with antithymocyte antibody-containing conditioning regimen for graft failure in eight patients with severe aplastic anemia.

Autorzy:

Zhang C; Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, ShaHeKou District, Dalian, 116027, China.; Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, 116027, China.
Hou Y; Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, ShaHeKou District, Dalian, 116027, China.; Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, 116027, China.
Yang Y; Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, ShaHeKou District, Dalian, 116027, China.
Zhang J; Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, ShaHeKou District, Dalian, 116027, China. .; Department of Pediatric, Pediatric Oncology and Hematology Center, The Second Hospital of Dalian Medical University, Dalian, 116027, China. .
Zheng X; Department of Hematology, Air Force Medical Center, PLA, No. 3 Fuchen Road, Haidian District, Beijing, 100142, China. .
Yan J; Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, No. 467, Zhongshan Road, ShaHeKou District, Dalian, 116027, China. .; Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, The Second Hospital of Dalian Medical University, Dalian, 116027, China. .; Department of Pediatric, Pediatric Oncology and Hematology Center, The Second Hospital of Dalian Medical University, Dalian, 116027, China. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Jan 27; Vol. 14 (1), pp. 2293. Date of Electronic Publication: 2024 Jan 27.

Typ publikacji:

Journal Article

MeSH Terms:

Anemia, Aplastic*/therapy
Hematopoietic Stem Cell Transplantation*
Graft vs Host Disease*/etiology
Humans ; Child, Preschool ; Child ; Adolescent ; Young Adult ; Adult ; Bone Marrow Transplantation ; Retrospective Studies ; Antilymphocyte Serum/therapeutic use ; Transplantation Conditioning ; Cyclophosphamide

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 5.

Tytuł:

Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.

Autorzy:

Liu H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Zou H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Shan D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Liu W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Huang W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Sui W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Deng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Wang T; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Lv R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Fu M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Xu Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Yi S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
An G; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Zhao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.
Zou D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (2), pp. e6965.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Carmustine/adverse effects ; Gemcitabine ; Melphalan/adverse effects ; Retrospective Studies ; Transplantation, Autologous/methods ; Cyclophosphamide/therapeutic use ; Etoposide/adverse effects ; Cytarabine/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 6.

Tytuł:

Ten-Year Trends of Hematopoietic Stem Cell Transplantation in Korean Pediatric Cancer from the National Health Insurance Claims Data.

Autorzy:

Kim H; Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kim HJ; Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jo Y; Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yoon SH; Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Koh YK; Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Department of Pediatrics, Chosun University College of Medicine, Gwangju, Korea.
Kang S; Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Koh KN; Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Im HJ; Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Pokaż więcej

Źródło:

Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 294-304. Date of Electronic Publication: 2023 Sep 07.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Neoplasms*/epidemiology
Neoplasms*/therapy
Adolescent ; Humans ; Child ; Registries ; Transplantation Conditioning ; Republic of Korea/epidemiology ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 7.

Tytuł:

Higher cyclosporine-A concentration increases the risk of relapse in AML following allogeneic stem cell transplantation from unrelated donors using anti-thymocyte globulin.

Autorzy:

Lisak M; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Bruna stråket 5, plan 5, 413 45, Gothenburg, Sweden. .; Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. .
Nicklasson M; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Bruna stråket 5, plan 5, 413 45, Gothenburg, Sweden.
Palmason R; Department of Hematology, Skane University Hospital, Lund, Sweden.
Wichert S; Department of Hematology, Skane University Hospital, Lund, Sweden.
Isaksson C; Department of Hematology, Norrland University Hospital, Umeå, Sweden.
Andersson PO; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Bruna stråket 5, plan 5, 413 45, Gothenburg, Sweden.; Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Johansson JE; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Bruna stråket 5, plan 5, 413 45, Gothenburg, Sweden.; Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Lenhoff S; Department of Hematology, Skane University Hospital, Lund, Sweden.
Brune M; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Bruna stråket 5, plan 5, 413 45, Gothenburg, Sweden.; Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Hansson M; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Bruna stråket 5, plan 5, 413 45, Gothenburg, Sweden.; Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.; Department of Hematology, Skane University Hospital, Lund, Sweden.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Dec 20; Vol. 13 (1), pp. 22777. Date of Electronic Publication: 2023 Dec 20.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/therapy
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Graft vs Host Disease*/epidemiology
Humans ; Cyclosporine/therapeutic use ; Antilymphocyte Serum/therapeutic use ; Unrelated Donors ; Acute Disease ; Recurrence ; Retrospective Studies ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 8.

Tytuł:

Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation.

Autorzy:

Chen X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Ma Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Zhang R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Zhai W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Ma Q; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Pang A; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Yang D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Wei J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
He Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Song Z; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Feng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Han M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.
Jiang E; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, People's Republic of China.; Tianjin Institutes of Health Science, Tianjin, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2212943.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Graft vs Host Disease*/pathology
Female ; Humans ; Animals ; Swine ; Antilymphocyte Serum/therapeutic use ; Siblings ; Neoplasm Recurrence, Local ; Chronic Disease ; Transplantation Conditioning/adverse effects ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 9.

Tytuł:

Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.

Autorzy:

Cao J; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Xu X; Department of Oncology, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China.
Lu Y; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Wang T; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Chen D; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Li S; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Liu X; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Ye P; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.
Zheng ZZ; Shanghai Tissuebank Biotechnology Co., Ltd., Shanghai, People's Republic of China.
Pei R; Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, People's Republic of China.; Institute of Hematology, Ningbo University, Ningbo, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2223873.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/drug therapy
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematologic Neoplasms*/therapy
Adult ; Humans ; Child ; Cyclophosphamide/therapeutic use ; Busulfan/therapeutic use ; Antilymphocyte Serum/therapeutic use ; Acute Disease ; Transplantation Conditioning ; Cytarabine/therapeutic use ; Recurrence ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 10.

Tytuł:

Can doses of post-transplantation cyclophosphamide in haploidentical stem cell allografts be reduced?

Autorzy:

Olivares-Gazca JC; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Pastelín-Martínez ML; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Anáhuac Puebla, Puebla, México.
Montes-Robles MA; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Anáhuac Puebla, Puebla, México.
Gallardo-Pérez MM; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Hernández-Flores EJ; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Robles-Nasta M; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Sánchez-Bonilla D; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Ruiz-Delgado GJ; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.
Ruiz-Argüelles GJ; Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México.; Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, México.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2242176.

Typ publikacji:

Journal Article

MeSH Terms:

Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans ; Prospective Studies ; Cyclophosphamide ; Transplantation Conditioning/methods ; Allografts ; Stem Cells ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 11.

Tytuł:

Metformin pretreatment ameliorates busulfan-induced liver endothelial toxicity during haematopoietic stem cell transplantation.

Autorzy:

Balakrishnan B; Department of Haematology, Christian Medical College, Vellore, India.
Illangeswaran RSS; Department of Haematology, Christian Medical College, Vellore, India.
Rajamani BM; Department of Haematology, Christian Medical College, Vellore, India.
Arunachalam AK; Department of Haematology, Christian Medical College, Vellore, India.
Pai AA; Department of Haematology, Christian Medical College, Vellore, India.
Mohanan E; Department of Haematology, Christian Medical College, Vellore, India.
Srivastava A; Department of Haematology, Christian Medical College, Vellore, India.; Centre for Stem Cell Research (CSCR), A Unit of InStem Bengaluru, Christian Medical College Campus, Vellore, India.
Mathews V; Department of Haematology, Christian Medical College, Vellore, India.
Balasubramanian P; Department of Haematology, Christian Medical College, Vellore, India.; Centre for Stem Cell Research (CSCR), A Unit of InStem Bengaluru, Christian Medical College Campus, Vellore, India.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Oct 26; Vol. 18 (10), pp. e0293311. Date of Electronic Publication: 2023 Oct 26 (Print Publication: 2023).

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Busulfan*/toxicity
Busulfan*/therapeutic use
Hematopoietic Stem Cell Transplantation*
Mice ; Animals ; Endothelial Cells ; Liver ; Transplantation Conditioning

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 12.

Tytuł:

Infections and risk factors for infection-related mortality after pediatric allogeneic hematopoietic stem cell transplantation in Mexico: A single center retrospective study.

Autorzy:

Jiménez-Hernández E; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.; Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Núñez-Enriquez JC; Unidad de Investigación Médica en Epidemiología Clínica, UMAE, Hospital de Pediatría, CMN 'Siglo XXI', IMSS, Mexico City, Mexico.
Arellano-Galindo J; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
de Los Angeles Del Campo-Martínez M; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Reynoso-Arenas PV; Servicio de Hematología Pediátrica, UMAE, CMN 'La Raza' del IMSS, Mexico City, Mexico.
Reyes-López A; Centro de Estudios Económicos y Sociales en Salud, Hospital Infantil de México Federico Gómez, de la Secretaría de Salud, México City, Mexico.
Delgado-Gaytan AV; Laboratorio Clínico, Sección de Microbiología, UMAE, CMN 'La Raza' del IMSS, Mexico City, Mexico.
Del Socorro Méndez-Tovar M; Centro Estatal de Cancerología, 'Dr. Miguel Dorantes-Mesa', Secretaría de Salud, Xalapa Veracruz, México.
Marín-Palomares T; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Dueñas-Gonzalez MT; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Ortíz-Fernández A; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Montero-Ponce I; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Espinosa-Hernández LE; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Núñez-Villegas NN; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Pérez-Casillas R; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Sánchez-Jara B; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
García-Soto A; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Herver-Olivares AN; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Jaimes-Reyes EZ; Centro Estatal de Cancerología, 'Dr. Miguel Dorantes-Mesa', Secretaría de Salud, Xalapa Veracruz, México.
Tiznado-García HM; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Martínez-Villegas O; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Valdez-Garibay B; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Del Rocío Loza-Santiaguillo P; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
García-Jiménez X; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.; Hospital Pediátrico Coyoacán, Secretaría de Salud Gobierno de la Ciudad de México, Mexico City, México.
Ortíz-Torres G; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Fernández-Castillo GJ; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Aguilar-Olivares DM; Servicio de Hematología Pediátrica y Unidad de Trasplante de Médula Osea, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional (CMN)' La Raza', Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
Díaz-Padilla LA; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
Noya-Rodríguez MA; Laboratorio de Virología Clínica y Experimental, Unidad de Investigación Unidad de Investigación en Enfermedades Infecciosas, Hospital Infantil de México 'Federico Gómez' Ciudad de México, México, Mexico.
García-Jiménez M; Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Mejía-Aranguré JM; Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.; Unidad de Investigación Médica en Epidemiología Clínica, UMAE, Hospital de Pediatría, CMN 'Siglo XXI', IMSS, Mexico City, Mexico.; Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Sep 29; Vol. 18 (9), pp. e0284628. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Mycoses*/etiology
Humans ; Child ; Adolescent ; Retrospective Studies ; Mexico/epidemiology ; Transplantation, Homologous/adverse effects ; Risk Factors ; Unrelated Donors ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 13.

Tytuł:

Potential factors for and the prognostic impact of ascites after allogeneic hematopoietic stem cell transplantation.

Autorzy:

Kubo H; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.
Imataki O; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan. .
Fukumoto T; Department of Hematology, Takamatsu Red Cross Hospital, Takamatsu, Kagawa, Japan.
Kawanaka Y; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.
Ishida T; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.
Kubo YH; Department of Hematology, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan.
Kida JI; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.
Uemura M; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.
Fujita H; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.
Kadowaki N; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-Town, Kita-County, Kagawa, 761-0793, Japan.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 Aug 10; Vol. 13 (1), pp. 13005. Date of Electronic Publication: 2023 Aug 10.

Typ publikacji:

Journal Article

MeSH Terms:

Graft vs Host Disease*/diagnosis
Hematopoietic Stem Cell Transplantation*/adverse effects
Thrombotic Microangiopathies*/diagnosis
Thrombotic Microangiopathies*/epidemiology
Thrombotic Microangiopathies*/etiology
Humans ; Prognosis ; Ascites/complications ; Risk Factors ; Retrospective Studies ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 14.

Tytuł:

Association between conditioning intensity and height growth after allogeneic hematopoietic stem cell transplantation in children.

Autorzy:

Uemura S; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Hasegawa D; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Kishimoto K; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Fujikawa T; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Nakamura S; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Kozaki A; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Saito A; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Ishida T; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Mori T; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Ozaki K; Department of Endocrinology and Metabolism, Kobe Children's Hospital, Kobe, Japan.
Kosaka Y; Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 17018-17027. Date of Electronic Publication: 2023 Jul 11.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Bronchiolitis Obliterans Syndrome*
Humans ; Child ; Transplantation, Homologous ; Busulfan ; Transplantation Conditioning/adverse effects ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 15.

Tytuł:

Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.

Autorzy:

Edahiro T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Kawase T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Nagoshi H; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Fujino K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Toishigawa K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Miyama T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Mino T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Yoshida T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Morioka T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Hirata Y; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Noma M; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Fujii T; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Nishizawa M; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Fukushima N; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 186-198.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hematologic Neoplasms/*therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Busulfan/administration & dosage ; Combined Modality Therapy ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/mortality ; Humans ; Male ; Melphalan/administration & dosage ; Middle Aged ; Myeloablative Agonists/administration & dosage ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 16.

Tytuł:

A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.

Autorzy:

Zhang Y; Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, People's Republic of China.; The Second People's Hospital of Huai'an, Huai'an, People's Republic of China.
Liu L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Si Y; Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, People's Republic of China.; The Second People's Hospital of Huai'an, Huai'an, People's Republic of China.
Miao M; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Qiu H; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Tang X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Han Y; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Fu C; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Jin Z; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Chen S; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Sun A; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 741-750.

Typ publikacji:

Comparative Study; Journal Article

MeSH Terms:

Anemia, Aplastic/*therapy
Antilymphocyte Serum/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Adolescent ; Adult ; Animals ; Antilymphocyte Serum/adverse effects ; Child ; Child, Preschool ; Female ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Swine ; Transplantation Conditioning/adverse effects ; Transplantation, Homologous/adverse effects ; Transplantation, Homologous/methods ; Treatment Outcome ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 17.

Tytuł:

Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts.

Autorzy:

Lu Y; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Xiong M; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Sun RJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Zhao YL; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Zhang JP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Cao XY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Liu DY; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Wei ZJ; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Zhou JR; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.
Lu DP; Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 134-143.

Typ publikacji:

Journal Article

MeSH Terms:

Congenital Bone Marrow Failure Syndromes/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Graft Survival ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Survival Analysis ; Transplantation Conditioning/adverse effects ; Unrelated Donors ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 18.

Tytuł:

Safety and efficacy of a nonmyeloablative pretransplant conditioning regimen using total lymphoid irradiation with volumetric modulated arc therapy in healthy dogs: A pilot study.

Autorzy:

Kim S; Laboratory of Veterinary Surgery, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Hosoya K; Laboratory of Advanced Veterinary Medicine, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Fukayama N; Laboratory of Advanced Veterinary Medicine, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Deguchi T; Graduate School of Veterinary Medicine, Veterinary Teaching Hospital, Hokkaido University, Sapporo, Japan.
Okumura M; Laboratory of Veterinary Surgery, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.

Pokaż więcej

Źródło:

Veterinary medicine and science [Vet Med Sci] 2021 Jul; Vol. 7 (4), pp. 1120-1130. Date of Electronic Publication: 2021 Mar 13.

Typ publikacji:

Journal Article

MeSH Terms:

Dogs/*surgery
Hematopoietic Stem Cell Transplantation/*veterinary
Lymphatic Irradiation/*veterinary
Radiotherapy, Intensity-Modulated/*veterinary
Transplantation Conditioning/*veterinary
Animals ; Hematopoietic Stem Cell Transplantation/methods ; Male ; Pilot Projects ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 19.

Tytuł:

Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.

Autorzy:

van der Stoep MYEC; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, Leiden, The Netherlands. .; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands. .
Berghuis D; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Bredius RGM; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Buddingh EP; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Mohseny AB; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Smiers FJW; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, Leiden, The Netherlands.
Lankester AC; Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, Leiden, The Netherlands.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2021 Sep 27; Vol. 11 (1), pp. 19084. Date of Electronic Publication: 2021 Sep 27.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Busulfan/*analogs & derivatives
Data Mining/*methods
Hematopoietic Stem Cell Transplantation/*adverse effects
Myalgia/*diagnosis
Transplantation Conditioning/*adverse effects
Adolescent ; Busulfan/adverse effects ; Child ; Child, Preschool ; Electronic Health Records/statistics & numerical data ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Humans ; Male ; Myalgia/chemically induced ; Myalgia/epidemiology ; Pain Measurement/statistics & numerical data ; Retrospective Studies ; Severity of Illness Index ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 20.

Tytuł:

Survivors of allogeneic bone marrow transplants in childhood report no significant long-term respiratory symptoms: A single-center analysis over 20 years.

Autorzy:

Ball J; Bristol Haematology and Oncology Centre, Bristol, UK.
Growcott S; Bristol Haematology and Oncology Centre, Bristol, UK.
Cameron A; Bristol Haematology and Oncology Centre, Bristol, UK.

Pokaż więcej

Źródło:

Pediatric transplantation [Pediatr Transplant] 2021 Aug; Vol. 25 (5), pp. e13957. Date of Electronic Publication: 2020 Dec 22.

Typ publikacji:

Journal Article

MeSH Terms:

Postoperative Complications*/diagnosis
Postoperative Complications*/epidemiology
Bone Marrow Transplantation/*adverse effects
Lung Diseases/*etiology
Transplantation Conditioning/*adverse effects
Whole-Body Irradiation/*adverse effects
Adolescent ; Adult ; Bone Marrow Transplantation/methods ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Infant ; Lung Diseases/diagnosis ; Lung Diseases/epidemiology ; Male ; Outcome Assessment, Health Care ; Retrospective Studies ; Transplantation Conditioning/methods ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 21.

Tytuł:

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.

Autorzy:

Nagler A; Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel. .
Labopin M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Blaise D; Programme de Transplantation and Therapie Cellulaire Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Raiola AM; Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Corral LL; Hospital Clínico Servicio de Hematología, Salamanca, Spain.
Bramanti S; Transplantation Unit Department of Oncology and Haematology, Istituto Clinico Humanitas, Milan, Italy.
Sica S; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Kwon M; Hematology Hospital GU Gregorio Marañon, Instituto de Investigacion Sanitaria Gregorio Marañon, Medicina UCM, Madrid, Spain.
Koc Y; Bone Marrow Transplant Unit, Medicana International Hospital Istanbul, Istanbuls, Turkey.
Pavlu J; Department of Haematology, Hammersmith Hospital, Imperial College, London, UK.
Kulagin A; Raisa Gorbacheva Memorial, Research Institute for Paediatric Oncology, Hematology, and Transplantation, First State Pavlov Medical University of St. Petersburg, St. Petersburg, Russia.
Busca A; SSD Trapianto di Cellule Staminali, AOU Citta' Della Salute e della Scienza, Turin, Italy.
Rodríguez AB; Hospital U. Marqués de Valdecilla, Servicio de Hematología-Hemoterapia, Santander, Spain.
Reményi P; Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Department Hematology and Stem Cell Transplant, Budapest, Hungary.
Schmid C; Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany.
Brissot E; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne University, and INSERM UMRs 938, Paris, France.
Sanz J; Hematology Department, Hospital Universitari Politècnic La Fe, Valencia, Spain.
Bazarbachi A; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Giebel S; Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Ciceri F; Ospedale San Raffaele, Haematology and BMT, Milan, Italy.
Mohty M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.

Pokaż więcej

Źródło:

Journal of hematology & oncology [J Hematol Oncol] 2023 May 29; Vol. 16 (1), pp. 58. Date of Electronic Publication: 2023 May 29.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/complications
Graft vs Host Disease*/etiology
Adult ; Humans ; Middle Aged ; Transplantation, Haploidentical/methods ; Cyclophosphamide/therapeutic use ; Recurrence ; Transplantation Conditioning/methods ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 22.

Tytuł:

Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis.

Autorzy:

Wu H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Zhao Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Gao F; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Shi J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Luo Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Yu J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Lai X; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Liu L; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Fu H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China.; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Qian P; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China.
Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China. .; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. .; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China. .; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China. .
Zhao Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79, Qingchun Road, Shangcheng District, Hangzhou, 310006, Zhejiang, People's Republic of China. .; Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. .; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, People's Republic of China. .; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, Zhejiang, People's Republic of China. .

Pokaż więcej

Źródło:

Journal of translational medicine [J Transl Med] 2023 May 18; Vol. 21 (1), pp. 329. Date of Electronic Publication: 2023 May 18.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematologic Neoplasms*/therapy
Hematologic Neoplasms*/complications
Humans ; Siblings ; Retrospective Studies ; Prospective Studies ; Propensity Score ; Neoplasm Recurrence, Local ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 23.

Tytuł:

Oral health in patients scheduled for hematopoietic stem cell transplantation in the Orastem study.

Autorzy:

Skallsjö K; Department of Oral medicine and Pathology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
von Bültzingslöwen I; Department of Oral Microbiology and Immunology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Hasséus B; Department of Oral medicine and Pathology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Johansson JE; Department of Hematology and Coagulation, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Öhman J; Department of Oral medicine and Pathology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Raber-Durlacher JE; Department of Oral Medicine, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, Amsterdam, The Netherlands.; Department of Oral and Maxillofacial Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Huysmans MDNJM; Department of Dentistry, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Laheij AMGA; Department of Oral Medicine, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, Amsterdam, The Netherlands.; Department of Oral and Maxillofacial Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.; Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, Amsterdam, The Netherlands.
van Leeuwen SJM; Department of Dentistry, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Hovan AJ; Oral Oncology and Dentistry, British Columbia Cancer, Vancouver, British Columbia, Canada.
Garming Legert K; Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.
Nguyen HM; Center for Outcomes Research and Evaluation, Atrium Health, Charlotte, North Carolina, United States of America.
Turk PJ; Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi, United States of America.
Rozema FR; Department of Oral Medicine, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, Amsterdam, The Netherlands.; Department of Oral and Maxillofacial Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Blijlevens NMA; Department of Hematology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Brennan MT; Department of Oral Medicine/Oral & Maxillofacial Surgery, Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States of America.; Department of Otolaryngology/Head and Neck Surgery, Wake Forest University School of Medicine, Wake Forest, North Carolina, United States of America.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 May 18; Vol. 18 (5), pp. e0285615. Date of Electronic Publication: 2023 May 18 (Print Publication: 2023).

Typ publikacji:

Observational Study; Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Dental Caries*/complications
Mouth Diseases*/epidemiology
Mouth Diseases*/etiology
Mouth Diseases*/diagnosis
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Oral Health ; Prospective Studies ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 24.

Tytuł:

Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation.

Autorzy:

Tamaki M; Division of Hematology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan. .
Akahoshi Y; Division of Hematology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Ashizawa M; Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
Misaki Y; Division of Hematology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
Koi S; Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Kim SW; Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
Ozawa Y; Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Fujiwara SI; Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
Kako S; Division of Hematology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.
Matsuoka KI; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Sawa M; Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Katayama Y; Department of Hematology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Onizuka M; Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Kanda Y; Division of Hematology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan.; Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
Fukuda T; Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.; Department of Registry Science for Transplantation and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
Yakushijin K; Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Nakasone H; Division of Hematology, Jichi Medical University Saitama Medical Center, 1-847 Amanuma-cho, Omiya-ku, Saitama, 330-8503, Japan. .; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, 329-0498, Japan. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2023 May 03; Vol. 13 (1), pp. 7166. Date of Electronic Publication: 2023 May 03.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Graft vs Host Disease*/etiology
Humans ; Male ; Female ; Antilymphocyte Serum/therapeutic use ; Retrospective Studies ; Tissue Donors ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 25.

Tytuł:

Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T-cell lymphoblastic lymphoma.

Autorzy:

Wei R; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Fang J; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shi W; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lu X; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiang S; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang A; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liao S; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qin C; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cui G; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xia L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 May; Vol. 12 (9), pp. 10499-10511. Date of Electronic Publication: 2023 Mar 29.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Graft vs Host Disease*/etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Lymphoma, T-Cell*
Lymphoma, T-Cell, Peripheral*
Humans ; Transplantation, Haploidentical ; Retrospective Studies ; Siblings ; Positron Emission Tomography Computed Tomography ; T-Lymphocytes ; Neoplasm Recurrence, Local ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 26.

Tytuł:

Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation.

Autorzy:

Gjaerde LK; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ostrowski SR; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Minculescu L; Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Andersen NS; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Friis LS; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Kornblit B; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Petersen SL; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Schjødt I; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Sengeløv H; Bone Marrow Transplant Unit, Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Pokaż więcej

Źródło:

European journal of haematology [Eur J Haematol] 2021 Mar; Vol. 106 (3), pp. 417-424. Date of Electronic Publication: 2020 Dec 19.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Graft vs Host Disease/*blood
Graft vs Host Disease/*etiology
Vitamin E/*blood
Acute Disease ; Biomarkers ; Disease Susceptibility ; Female ; Graft vs Host Disease/diagnosis ; Humans ; Male ; Myeloablative Agonists/administration & dosage ; Postoperative Period ; Severity of Illness Index ; Time Factors ; Transplantation, Homologous

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 27.

Tytuł:

Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.

Autorzy:

Tian C; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. .
Li Y; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Liu S; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Chen Z; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Zhang Y; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Yu Y; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Yang H; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Zhao H; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Zhao Z; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Yuan T; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
Wang Y; Key Laboratory of Cancer Prevention and Therapy, Department of Hematology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2021 Feb 19; Vol. 11 (1), pp. 4273. Date of Electronic Publication: 2021 Feb 19.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Antibiotics, Antineoplastic/*administration & dosage
Idarubicin/*administration & dosage
Lymphoma, Non-Hodgkin/*therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Disease Management ; Female ; Humans ; Lymphoma, Non-Hodgkin/diagnosis ; Lymphoma, Non-Hodgkin/mortality ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Invasiveness ; Neoplasm Staging ; Prognosis ; Transplantation, Autologous ; Treatment Outcome ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 28.

Tytuł:

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.

Autorzy:

Hahn L; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Lim H; Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK, Canada.
Dusyk T; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Sabry W; Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Elemary M; Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Stakiw J; Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Danyluk P; Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Bosch M; Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, Saskatoon, SK, Canada. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2021 Jul 07; Vol. 11 (1), pp. 14071. Date of Electronic Publication: 2021 Jul 07.

Typ publikacji:

Journal Article

MeSH Terms:

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Neoplasms/*therapy
Transplantation Conditioning/*methods
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carmustine ; Cytarabine ; Etoposide ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Male ; Melphalan ; Middle Aged ; Neoplasms/diagnosis ; Neoplasms/mortality ; Outcome Assessment, Health Care ; Podophyllotoxin ; Transplantation Conditioning/adverse effects

SCR Protocol:

BEAM protocol; BEAM regimen

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 29.

Tytuł:

The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders.

Autorzy:

Lima ACM; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Bonfim C; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Getz J; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Dornelles LN; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
do Amaral GB; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Petterle RR; Department of Integrative Medicine, Federal University of Paraná, Curitiba, Brazil.
Loth G; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Nabhan SK; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Pereira NF; Immunogenetics Laboratory, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Pasquini R; Bone Marrow Transplantation Unit, Complexo Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.

Pokaż więcej

Źródło:

HLA [HLA] 2021 Jun; Vol. 97 (6), pp. 493-504. Date of Electronic Publication: 2021 May 02.

Typ publikacji:

Journal Article; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Alleles ; Cyclophosphamide ; Humans ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 30.

Tytuł:

Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution.

Autorzy:

Hughes K; Department of Pharmacy Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Garrity L; Department of Pharmacy Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Nelson AS; Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Lane A; Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Teusink-Cross A; Department of Pharmacy Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Pokaż więcej

Źródło:

Pediatric transplantation [Pediatr Transplant] 2021 Jun; Vol. 25 (4), pp. e14026. Date of Electronic Publication: 2021 Apr 24.

Typ publikacji:

Comparative Study; Evaluation Study; Journal Article

MeSH Terms:

Anticonvulsants/*therapeutic use
Busulfan/*adverse effects
Levetiracetam/*therapeutic use
Myeloablative Agonists/*adverse effects
Phenytoin/*therapeutic use
Seizures/*prevention & control
Transplantation Conditioning/*adverse effects
Adolescent ; Adult ; Child ; Child, Preschool ; Drug Administration Schedule ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Incidence ; Infant ; Male ; Retrospective Studies ; Seizures/chemically induced ; Seizures/epidemiology ; Transplantation Conditioning/methods ; Treatment Outcome ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 31.

Tytuł:

Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Autorzy:

Nagler A; Hematology Division, Chaim Sheba Medical Center, 52621, Tel Hashomer, Israel. .
Labopin M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Houhou M; ALWP of the EBMT Paris office, Paris, France.
Aljurf M; King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Mousavi A; Shariati Hospital, Hematology-Oncology and BMT Research, Tehran, Islamic Republic of Iran.
Hamladji RM; Service Hématologie Greffe de Moëlle, Centre Pierre Et Marie Curie, Alger, Algeria.
Al Zahrani M; King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Bondarenko S; Raisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, First Pavlov State Medical University, Saint-Petersburg, Russian Federation.
Arat M; Hematopoietic Stem Cell Transplantation Unit, Sisli Florence Nightingale Hospital, Istanbul, Turkey.
Angelucci E; Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Koc Y; Medicana International, Istanbul, Turkey.
Gülbas Z; Bone Marrow Transplantation Department, Anadolu Medical Center Hospital, Kocaeli, Turkey.
Sica S; Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.; Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, France.
Bourhis JH; Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.
Canaani J; Hematology Division, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Brissot E; Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
Giebel S; Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Mohty M; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.

Pokaż więcej

Źródło:

Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 01; Vol. 14 (1), pp. 53. Date of Electronic Publication: 2021 Apr 01.

Typ publikacji:

Journal Article; Multicenter Study

MeSH Terms:

Hematopoietic Stem Cell Transplantation/*methods
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Transplantation Conditioning/*methods
Transplantation, Haploidentical/*methods
Adolescent ; Adult ; Aged ; Europe ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Retrospective Studies ; Siblings ; Survival Analysis ; Tissue Donors ; Transplantation Conditioning/mortality ; Transplantation, Haploidentical/mortality ; Treatment Outcome ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 32.

Tytuł:

Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Autorzy:

Graves SS; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Storb R; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; University of Washington School of Medicine, Seattle, Washington, USA.

Pokaż więcej

Źródło:

Veterinary and comparative oncology [Vet Comp Oncol] 2020 Dec; Vol. 18 (4), pp. 471-483. Date of Electronic Publication: 2020 May 26.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Transplantation Conditioning*/methods
Transplantation Conditioning*/veterinary
Dog Diseases/*therapy
Hematopoietic Stem Cell Transplantation/*veterinary
Animals ; Bone Marrow Transplantation/methods ; Bone Marrow Transplantation/veterinary ; Dogs ; Graft vs Host Disease/prevention & control ; Graft vs Host Disease/veterinary ; Hematopoietic Stem Cell Transplantation/methods ; Neoplasms/therapy ; Neoplasms/veterinary

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 33.

Tytuł:

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.

Autorzy:

Faisal MS; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.; Division of Hematology and Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
Hanel W; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Voorhees T; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Li R; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Huang Y; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Khan A; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Bond D; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Sawalha Y; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Reneau J; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Alinari L; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Baiocchi R; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Christian B; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Maddocks K; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Efebera Y; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.; Division of Hematology and Oncology, OhioHealth Bing Cancer Center, Columbus, Ohio, USA.
Penza S; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Saad A; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Brammer J; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
DeLima M; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Jaglowski S; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Epperla N; Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 Apr; Vol. 12 (7), pp. 8228-8237. Date of Electronic Publication: 2023 Jan 18.

Typ publikacji:

Journal Article

MeSH Terms:

Hodgkin Disease*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Humans ; Brentuximab Vedotin/therapeutic use ; Neoplasm Recurrence, Local ; Chronic Disease ; Transplantation Conditioning ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 34.

Tytuł:

Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Autorzy:

Ye Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Labopin M; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France.
Chen J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Gulbas Z; Anadolu Medical Center Hospital Bone Marrow Transplantation Department, Kocaeli, Turkey.
Zhang X; Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China.
Koc Y; Medicana International Hospital Istanbul, Bone Marrow Transplant Unit, Istanbul, Turkey.
Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Ciceri F; Ospedale San Raffaele S.R.L., Haematology and BMT, Milan, Italy.
Polge E; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France.
Houhou M; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France.
Li L; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Luo Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China. .
Mohty M; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France. .; Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France. .; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. .
Gorin NC; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France. .; Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France. .; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. .

Pokaż więcej

Źródło:

Journal of hematology & oncology [J Hematol Oncol] 2023 Mar 18; Vol. 16 (1), pp. 25. Date of Electronic Publication: 2023 Mar 18.

Typ publikacji:

Letter; Research Support, Non-U.S. Gov't

MeSH Terms:

Leukemia, Myeloid, Acute*
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Adult ; Humans ; Bone Marrow ; Acute Disease ; Recurrence ; Retrospective Studies ; Transplantation Conditioning/adverse effects

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 35.

Tytuł:

Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation.

Autorzy:

Dong J; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, HRC 5860, Milwaukee, WI, 53226, USA. .; Medical College of Wisconsin Cancer Center, Milwaukee, WI, USA. .; Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. .
Buradagunta CS; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, HRC 5860, Milwaukee, WI, 53226, USA.
Zhang T; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program®/Be The Match®, Minneapolis, MN, USA.
Spellman S; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program®/Be The Match®, Minneapolis, MN, USA.
Bolon YT; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program®/Be The Match®, Minneapolis, MN, USA.
DeZern AE; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, USA.
Gadalla SM; Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, MD, USA.
Deeg HJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Nazha A; Cleveland Clinic Foundation, Cleveland, OH, USA.
Cutler C; Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA, USA.
Cheng C; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Urrutia R; Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Auer P; Division of Biostatistics, Institute for Health & Equity, and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.; Division of Hematology and Oncology, Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA.; Cancer Center Biostatistics Shared Resource, Medical College of Wisconsin, Milwaukee, WI, USA.
Saber W; Division of Hematology and Oncology, Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA. .

Pokaż więcej

Źródło:

Journal of hematology & oncology [J Hematol Oncol] 2023 Mar 10; Vol. 16 (1), pp. 21. Date of Electronic Publication: 2023 Mar 10.

Typ publikacji:

Letter; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

MeSH Terms:

Genome, Mitochondrial*
Hematopoietic Stem Cell Transplantation*
Myelodysplastic Syndromes*/genetics
Humans ; Prognosis ; Transplantation Conditioning ; DNA, Mitochondrial ; Retrospective Studies

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 36.

Tytuł:

Peripheral blood kinetics following total body irradiation and allogeneic hematopoietic stem cell transplantation: Timing matters.

Autorzy:

Dejonckheere CS; Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Böhner AMC; Institute of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany.
Schmitz E; Department of Neurology, University Hospital Bonn, Bonn, Germany.
Holderried TAW; Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Schmeel LC; Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Brossart P; Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Giordano FA; Department of Radiation Oncology, University Medical Center Mannheim, Mannheim, Germany.
Köksal MA; Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany.

Pokaż więcej

Źródło:

Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (6), pp. 7170-7174. Date of Electronic Publication: 2022 Nov 20.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/complications
Graft vs Host Disease*/etiology
Adult ; Humans ; Retrospective Studies ; Whole-Body Irradiation ; Kinetics ; Transplantation Conditioning/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 37.

Tytuł:

Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.

Autorzy:

Lin M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Wu X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhang L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Li L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Wang X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Fu X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Sun Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhang X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhu L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Yu H; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Chang Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Nan F; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Yan J; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhou Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Shi C; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.
Li X; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, P.R. China.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 605-612. Date of Electronic Publication: 2023 Jan 19.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma*/diagnosis
Lymphoma*/therapy
Humans ; Etoposide/adverse effects ; Retrospective Studies ; Transplantation, Autologous ; Cytarabine/adverse effects ; Cyclophosphamide/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Transplantation Conditioning

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 38.

Tytuł:

Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders.

Autorzy:

Tannumsaeung S; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.
Anurathapan U; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.
Pakakasama S; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.
Pongpitcha P; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.
Songdej D; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.
Sirachainan N; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.
Andersson BS; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hongeng S; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Krung Thep Maha Nakhon (Bangkok), Thailand.

Pokaż więcej

Źródło:

European journal of haematology [Eur J Haematol] 2023 Mar; Vol. 110 (3), pp. 305-312. Date of Electronic Publication: 2022 Dec 07.

Typ publikacji:

Journal Article

MeSH Terms:

Graft vs Host Disease*/diagnosis
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematologic Neoplasms*
Humans ; Child ; Thiotepa ; Neoplasm Recurrence, Local/drug therapy ; T-Lymphocytes/pathology ; Cyclophosphamide/therapeutic use ; Busulfan/therapeutic use ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 39.

Tytuł:

Hematopoietic stem cell transplantation in serine/threonine kinase 4 (STK4) deficiency: Report of two cases and literature review.

Autorzy:

Uygun V; Faculty of Medicine, MedicalPark Antalya Hospital, Department Of Pediatric Bone Marrow Transplantation Unit, İstinye University, Antalya, Turkey.
Keleş S; Meram Medical Faculty, Division of Pediatric Immunology and Allergy, Necmettin Erbakan University, Konya, Turkey.
Daloğlu H; Faculty of Health Sciences, MedicalPark Antalya Hospital, Department Of Pediatric Bone Marrow Transplantation Unit, Antalya Bilim University, Antalya, Turkey.
Öztürkmen S; Department Of Pediatric Bone Marrow Transplantation Unit, MedicalPark Antalya Hospital, Antalya, Turkey.
Yalçın K; Faculty of Medicine, MedicalPark Göztepe Hospital, Department Of Pediatric Bone Marrow Transplantation Unit, Bahçeşehir University, İstanbul, Turkey.
Karasu G; Department Of Pediatric Bone Marrow Transplantation Unit, MedicalPark Göztepe Hospital, İstanbul, Turkey.
Yeşilipek A; Department Of Pediatric Bone Marrow Transplantation Unit, MedicalPark Antalya Hospital, Antalya, Turkey.

Pokaż więcej

Źródło:

Pediatric transplantation [Pediatr Transplant] 2023 Mar; Vol. 27 (2), pp. e14439. Date of Electronic Publication: 2022 Nov 16.

Typ publikacji:

Review; Case Reports

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Humans ; Busulfan/therapeutic use ; Methotrexate/therapeutic use ; Rituximab/therapeutic use ; Sirolimus/therapeutic use ; Mycophenolic Acid/therapeutic use ; Unrelated Donors ; Protein Serine-Threonine Kinases/genetics ; Serine ; Transplantation Conditioning ; Vidarabine/therapeutic use ; Intracellular Signaling Peptides and Proteins

Recenzja

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 40.

Tytuł:

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT.

Autorzy:

Baron F; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Sart-Tilman, 4000, Liège, Belgium. .
Labopin M; EBMT Paris Study Office/CEREST-TC, Paris, France.; Department of Hematology, Saint Antoine Hospital, Paris, France.; INSERM UMR 938, Paris, France.; Sorbonne University, Paris, France.
Tischer J; Department of Internal Medicine III, LMU, University Hospital of Munich, Campus Grosshadern, Munich, Germany.
Raiola AM; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Vydra J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Blaise D; Programme de Transplantation et d'immunothérapie Cellulaire, Management Sport Cancer Lab, Institut Paoli Calmettes, Aix Marseille University, Marseille, France.
Chiusolo P; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Stölzel F; University Hospital Dresden, Medizinische Klinik und Poliklinik, TU Dresden, Dresden, Germany.; University Hospital Schleswig-Holstein, Kiel, Germany.
Fanin R; Division of Hematology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy.
Chevallier P; Dept. D`Hematologie, CHU Nantes, Nantes, France.
Nagler A; Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Ciceri F; Haematology and BMT, Ospedale San Raffaele S.R.L., Milan, Italy.
Mohty M; EBMT Paris Study Office/CEREST-TC, Paris, France.; Department of Hematology, Saint Antoine Hospital, Paris, France.; INSERM UMR 938, Paris, France.; Sorbonne University, Paris, France.

Pokaż więcej

Źródło:

Journal of hematology & oncology [J Hematol Oncol] 2023 Feb 13; Vol. 16 (1), pp. 10. Date of Electronic Publication: 2023 Feb 13.

Typ publikacji:

Letter; Research Support, Non-U.S. Gov't

MeSH Terms:

Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Graft vs Host Disease*/drug therapy
Leukemia, Myeloid, Acute*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Transplantation, Haploidentical/adverse effects ; Unrelated Donors ; Cyclophosphamide/therapeutic use ; Recurrence ; Transplantation Conditioning/adverse effects ; Retrospective Studies

Raport

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 41.

Tytuł:

Response to "Conditioning with melphalan (Mel) 200 mg/m and subsequent autologous stem cell transplantation improves progression free survival and overall survival in elderly multiple myeloma patients compared to standard of care".

Autorzy:

Caravita di Toritto T; UOSD Ematologia Asl Roma 1, Rome, Italy.
Rago A; UOSD Ematologia Asl Roma 1, Rome, Italy.

Pokaż więcej

Źródło:

European journal of haematology [Eur J Haematol] 2023 Feb; Vol. 110 (2), pp. 221. Date of Electronic Publication: 2022 Nov 08.

Typ publikacji:

Letter; Comment

MeSH Terms:

Multiple Myeloma*/therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Aged ; Melphalan ; Progression-Free Survival ; Standard of Care ; Transplantation, Autologous ; Transplantation Conditioning

Opinia redakcyjna

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 42.

Tytuł:

Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study.

Autorzy:

Yui S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Wakita S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Nagata Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kuribayashi Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Asayama T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Fujiwara Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Sakaguchi M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Yamanaka S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Marumo A; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Omori I; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kinoshita R; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Onai D; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Sunakawa M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kaito Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Inai K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Tokura T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Takeyoshi A; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Yasuda S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Honma S; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Nakayama K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Hirakawa T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Arai K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Kitano T; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Okamoto M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Inokuchi K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Yamaguchi H; Department of Hematology, Nippon Medical School, Tokyo, Japan.

Pokaż więcej

Źródło:

Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2023 Feb; Vol. 19 (1), pp. 136-148. Date of Electronic Publication: 2022 May 22.

Typ publikacji:

Journal Article

MeSH Terms:

Peripheral Blood Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/adverse effects
Lymphoma, Large B-Cell, Diffuse*
Humans ; Cytarabine/adverse effects ; Retrospective Studies ; Transplantation, Autologous ; Etoposide/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Melphalan/adverse effects ; Transplantation Conditioning/methods ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 43.

Tytuł:

Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.

Autorzy:

Kumar L; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sahoo RK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar S; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Baa AK; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Tansir G; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Pathak N; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Malik PS; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma OD; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Mathew A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Jha A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Gupta R; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Sharma A; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Biswas A; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Kumar R; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Thulkar S; Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, India.
Malik S; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Dutt A; Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.

Pokaż więcej

Corporate Authors:

for AIIMS Myeloma Group

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 378-387. Date of Electronic Publication: 2022 Nov 23.

Typ publikacji:

Journal Article

MeSH Terms:

Multiple Myeloma*/therapy
Multiple Myeloma*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Melphalan/adverse effects ; Transplantation, Autologous ; Neoplasm Recurrence, Local/drug therapy ; Stem Cell Transplantation ; Treatment Outcome ; Transplantation Conditioning/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 44.

Tytuł:

Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.

Autorzy:

Klyuchnikov E; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Langebrake C; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.; Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Badbaran A; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Dadkhah A; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.; Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Massoud R; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Freiberger P; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Ayuk F; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Janson D; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Wolschke C; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Bacher U; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
Kröger N; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.

Pokaż więcej

Źródło:

European journal of haematology [Eur J Haematol] 2023 Feb; Vol. 110 (2), pp. 188-197. Date of Electronic Publication: 2022 Dec 01.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/therapy
Leukemia, Myeloid, Acute*/etiology
Graft vs Host Disease*/diagnosis
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Humans ; Busulfan/adverse effects ; Neoplasm, Residual ; Transplantation, Homologous ; Recurrence ; Transplantation Conditioning ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 45.

Tytuł:

Non-myeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies.

Autorzy:

Shin SH; Department of Hematology, Hematology Institute, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park SS; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park S; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jeon YW; Department of Hematology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yoon JH; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yahng SA; Department of Hematology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Cho BS; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim YJ; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Lee S; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim HJ; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Min CK; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Cho SG; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim DW; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Lee JW; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Eom KS; Leukemia Research Institute, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Pokaż więcej

Źródło:

European journal of haematology [Eur J Haematol] 2020 Oct; Vol. 105 (4), pp. 387-398. Date of Electronic Publication: 2020 Jul 10.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Siblings*
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Hemoglobinopathies/*therapy
Hemoglobinopathies/diagnosis ; Hemoglobinopathies/mortality ; Humans ; Prognosis ; Transplantation Chimera ; Transplantation, Homologous ; Treatment Outcome ; beta-Thalassemia/mortality ; beta-Thalassemia/therapy

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 46.

Tytuł:

Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis.

Autorzy:

Ma L; Department of Hematology, Second Affiliated Hospital of Nanjing Medical University, 121# Jiangjiayuan Road, Nanjing 210011, People's Republic of China.
Han X; Department of Hematology, Second Affiliated Hospital of Nanjing Medical University, 121# Jiangjiayuan Road, Nanjing 210011, People's Republic of China.
Jiang S; Department of Hematology, Second Affiliated Hospital of Nanjing Medical University, 121# Jiangjiayuan Road, Nanjing 210011, People's Republic of China.
Meng Q; Department of Hematology, Second Affiliated Hospital of Nanjing Medical University, 121# Jiangjiayuan Road, Nanjing 210011, People's Republic of China.
Zhang L; Department of Hematology, Second Affiliated Hospital of Nanjing Medical University, 121# Jiangjiayuan Road, Nanjing 210011, People's Republic of China.
Bao H; Department of Hematology, Second Affiliated Hospital of Nanjing Medical University, 121# Jiangjiayuan Road, Nanjing 210011, People's Republic of China.

Pokaż więcej

Źródło:

Hematology (Amsterdam, Netherlands) [Hematology] 2020 Dec; Vol. 25 (1), pp. 356-365.

Typ publikacji:

Comparative Study; Journal Article; Systematic Review; Video-Audio Media

MeSH Terms:

Graft vs Host Disease*/etiology
Graft vs Host Disease*/mortality
Graft vs Host Disease*/therapy
Hematologic Neoplasms*/mortality
Hematologic Neoplasms*/therapy
Hematopoietic Stem Cell Transplantation*
Transplantation Conditioning*
Unrelated Donors*
Adult ; Allografts ; Disease-Free Survival ; Female ; Humans ; Male

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 47.

Tytuł:

Lower intensity regimens for acute myeloid leukemia: opportunities and challenges.

Autorzy:

Ahmed M; Department of Internal Medicine, University of South Dakota, Sanford School of Medicine, Sioux Falls, SD, USA.
Pollyea DA; Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.

Pokaż więcej

Źródło:

Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 66-70. Date of Electronic Publication: 2022 Nov 02.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/epidemiology
Leukemia, Myeloid, Acute*/therapy
Hematologic Neoplasms*
Graft vs Host Disease*
Humans ; Aged ; Transplantation, Homologous ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/methods ; Retrospective Studies

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 48.

Tytuł:

Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILe implementation science project.

Autorzy:

Ribaut J; Department Public Health, Faculty of Medicine, Institute of Nursing Science, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.; Department of Hematology, University Hospital of Basel, 4031, Basel, Switzerland.
Leppla L; Department Public Health, Faculty of Medicine, Institute of Nursing Science, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.; Departments of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, 79110, Freiburg im Breisgau, Germany.
Teynor A; Department of Computer Science, University of Applied Sciences, Augsburg, Germany.
Valenta S; Department Public Health, Faculty of Medicine, Institute of Nursing Science, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.; Department of Hematology, University Hospital of Basel, 4031, Basel, Switzerland.
Dobbels F; Department Public Health, Faculty of Medicine, Institute of Nursing Science, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland.; Academic Center for Nursing and Midwifery, Department of Public Health and Primary Care, University of Leuven, 3000, Leuven, Belgium.
Zullig LL; Department of Population Health Science, Duke University, Durham, NC, USA.; Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, NC, USA.
De Geest S; Department Public Health, Faculty of Medicine, Institute of Nursing Science, University of Basel, Bernoullistrasse 28, 4056, Basel, Switzerland. .; Academic Center for Nursing and Midwifery, Department of Public Health and Primary Care, University of Leuven, 3000, Leuven, Belgium. .

Pokaż więcej

Corporate Authors:

SMILe study team

Źródło:

BMC health services research [BMC Health Serv Res] 2020 Sep 02; Vol. 20 (1), pp. 827. Date of Electronic Publication: 2020 Sep 02.

Typ publikacji:

Journal Article

MeSH Terms:

Hematopoietic Stem Cell Transplantation*
Implementation Science*
Medication Adherence*
Transplantation Conditioning*
Telemedicine/*methods
Humans ; Immunosuppressive Agents/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 49.

Tytuł:

Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.

Autorzy:

Huttunen P; Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Taskinen M; Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Vettenranta K; Division of Hematology-Oncology and Stem Cell Transplantation, New Children´s Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Pokaż więcej

Źródło:

Pediatric hematology and oncology [Pediatr Hematol Oncol] 2020 Aug; Vol. 37 (5), pp. 355-364. Date of Electronic Publication: 2020 Mar 13.

Typ publikacji:

Journal Article

MeSH Terms:

Antineoplastic Agents/*adverse effects
Busulfan/*analogs & derivatives
Hematologic Neoplasms/*therapy
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*adverse effects
Adolescent ; Antineoplastic Agents/therapeutic use ; Busulfan/adverse effects ; Busulfan/therapeutic use ; Child ; Child, Preschool ; Cyclophosphamide/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Infant ; Male ; Myeloablative Agonists/adverse effects ; Myeloablative Agonists/therapeutic use ; Retrospective Studies ; Transplantation Conditioning/methods ; Transplantation, Homologous ; Treatment Outcome ; Whole-Body Irradiation/methods

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 50.

Tytuł:

Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data.

Autorzy:

Yu S; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.; Department of Hematology, Nanhai Hospital, Southern Medical University, Foshan, China.
Huang F; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Fan Z; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Xuan L; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Nie D; Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, No.107 Yanjiang West Road, Guangzhou, 510120, China.
Xu Y; Department of Hematology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha, 410008, China.
Yang T; Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, No.29 Xinquan Road, Fuzhou, 350001, China.
Wang S; Department of Hematology, Guangzhou First People's Hospital, No.1 Fupan Road, Guangzhou, 510180, China.
Jiang Z; Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, No.111 Liuhua Road, Guangzhou, 510010, China.
Xu N; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Lin R; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Ye J; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Lin D; Department of Hematology, the Third Affiliated Hospital, Sun Yat-Sen University, No.600 Tianhe Road, Guangzhou, 510000, China.
Sun J; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.
Huang X; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China.; Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, No.11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China.
Wang Y; Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, No.11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China. .
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838 North Guangzhou Avenue, Guangzhou, 510515, China. .

Pokaż więcej

Źródło:

Journal of hematology & oncology [J Hematol Oncol] 2020 Mar 12; Vol. 13 (1), pp. 18. Date of Electronic Publication: 2020 Mar 12.

Typ publikacji:

Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

MeSH Terms:

Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Leukemia/*therapy
Adolescent ; Adult ; Female ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; HLA Antigens/genetics ; Humans ; Leukemia/genetics ; Lymphocyte Transfusion ; Male ; Middle Aged ; Prospective Studies ; Siblings ; Tissue Donors ; Transplantation, Haploidentical/adverse effects ; Transplantation, Haploidentical/methods ; Treatment Outcome ; Young Adult

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły